{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/cervical-cancer-hpv/management/management/","result":{"pageContext":{"chapter":{"id":"5d0f88a0-5a31-5e1f-81ee-89cc202d9885","slug":"management","fullItemName":"Scenario: Management","depth":2,"htmlHeader":"<!-- begin field b5ba319b-63d3-4a7a-8e74-9879ddcb9b24 --><h2>Scenario: Management</h2><!-- end field b5ba319b-63d3-4a7a-8e74-9879ddcb9b24 -->","summary":"Covers the treatment of confirmed cervical cancer in secondary care and management of specific problems associated with advanced cervical cancer in primary care.","htmlStringContent":"<!-- begin item e333479a-7bcf-4f5f-96fe-52860deb0f6f --><!-- begin field 0b550b8f-9c96-400b-b1f4-acbc0159f554 --><p>From age 16 years onwards (Female).</p><!-- end field 0b550b8f-9c96-400b-b1f4-acbc0159f554 --><!-- end item e333479a-7bcf-4f5f-96fe-52860deb0f6f -->","topic":{"id":"38328a3b-8997-55f8-afac-19e980523812","topicId":"e2dafa6e-4749-48b2-b981-fa906c90d627","topicName":"Cervical cancer and HPV","slug":"cervical-cancer-hpv","lastRevised":"Last revised in September 2020","chapters":[{"id":"417b3c03-a940-5eb6-8b35-698036862be5","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"b4186a4a-8c1e-51ad-9743-d00be5b18f3d","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"c2a58da0-8965-5522-8b3d-618890f730d3","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"2a436c60-1809-5f9f-bf39-409fd07e7af5","slug":"changes","fullItemName":"Changes"},{"id":"6b2a8979-8ca9-5087-a80b-ea14445c034a","slug":"update","fullItemName":"Update"}]},{"id":"c207e9ef-e492-5e67-8986-8b48ff76c55f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"4e791e8f-015d-58bd-99ec-2689c4baa3e4","slug":"goals","fullItemName":"Goals"},{"id":"b04fb3a0-7363-5d87-b475-a7ad1e7ca9af","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"af911672-6dba-57d0-b3bf-4058c30f91ff","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"16911bc4-aa1d-56b2-aaf3-39695a5692f3","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"9c781faa-cf3f-5dcc-b39d-4c10588cbbfb","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"713db7a4-b4c8-55f3-8ca0-e5c0db230466","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"2f3819e7-a39a-5399-98a2-014b4d9243c2","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e32e97af-cb99-5487-8ceb-1d8db9b2fe5f","slug":"types-of-cervical-cancer","fullItemName":"Types of cervical cancer"},{"id":"02013d86-5f8b-50e2-8bbc-9e9e5335f72d","slug":"causes","fullItemName":"Causes"},{"id":"961e80d0-b721-5756-b1df-56633ce9e5aa","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"4a62390f-59b9-5d3c-ad78-0394d8900138","slug":"prevalence","fullItemName":"Prevalence"},{"id":"5f216154-2a06-5aee-9270-f2388b590979","slug":"prognosis","fullItemName":"Prognosis"},{"id":"98782e4e-b481-5526-803b-b5f18e566c5d","slug":"complications","fullItemName":"Complications"}]},{"id":"0158af19-7ed5-56ac-a299-796dcf69f9a8","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"0a170049-907b-518b-9506-127d186d0a96","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"ae89986b-d468-50ca-b0d4-788dce1cc020","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"5aee8849-a5fc-592a-ba2f-161843f6a42e","slug":"cervical-cytology-sample","fullItemName":"Cervical cytology sample"},{"id":"8b13c601-cb6f-536e-a6cc-90001fa3357a","slug":"hpv-screening","fullItemName":"HPV screening"},{"id":"a05197b4-af3e-5fcb-9458-ec6446bb0cb9","slug":"referral","fullItemName":"Referral"}]},{"id":"75bee623-8a4b-5b31-b85b-b1f0cf45212d","fullItemName":"Management","slug":"management","subChapters":[{"id":"3918bf03-5c07-5c8f-bb28-5834e5dc1343","slug":"prevention","fullItemName":"Scenario: Prevention"},{"id":"5d0f88a0-5a31-5e1f-81ee-89cc202d9885","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"64ce0536-0d7d-554e-afc1-7859f158b82c","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"f4263e46-d3a8-5853-904f-7c0e9b926a1c","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"9b9af798-d073-5ea1-a174-157b46c68062","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"e827e587-3f77-5c14-92f8-58f34c105bbe","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"22b0924c-0e7d-5a46-b369-dd38ebbc4a39","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f012ac60-98ba-56b3-838a-7924e3544719","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"102ef6c4-0635-5f17-a33b-e2d83ec751b0","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"1f31eeae-6068-5e2c-8097-3666754f067e","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"75bee623-8a4b-5b31-b85b-b1f0cf45212d","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"aad84644-3170-547a-8f47-94f81a33d410","slug":"staging","fullItemName":"Staging","depth":3,"htmlHeader":"<!-- begin field abdfd18f-e6d3-4c06-a660-656e32e7d86e --><h3>What is the staging of cervical cancer?</h3><!-- end field abdfd18f-e6d3-4c06-a660-656e32e7d86e -->","summary":null,"htmlStringContent":"<!-- begin item 67e4f27c-4a09-4114-8ae9-de208b4961e2 --><!-- begin field 34efe91d-9f2e-42ee-9a1a-0db9d5fec6a7 --><p>The <a class=\"topic-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/management/management/#treatment\">management</a> of cervical cancer depends on the staging of the disease, which is based on clinical findings using the FIGO (Fédération Internationale des Gynaecologistes et Obstetristes) criteria and information obtained from medical imaging. </p><ul><li><strong>Cervical intraepithelial neoplasia (CIN) 3</strong>: carcinoma in situ — pre-invasive cancer.</li><li><strong>Stage I: </strong>The carcinoma is strictly confined to the cervix (extension to the uterus should be disregarded).<ul><li><strong>Stage IA:</strong> Diagnosed only by microscopy.<ul><li>Stage IA1: Measured stromal invasion of not more than 3 mm in depth, and extension of not more than 7 mm.</li><li>Stage IA2: Measured stromal invasion of between 3 mm and 5 mm in depth, and extension of not more than 7 mm.</li></ul></li><li><strong>Stage IB:</strong> Clinically visible lesions confined to the cervix, or preclinical cancers greater than stage 1A.<ul><li>Stage IB1: Lesions not more than 4 cm in size.</li><li>Stage IB2: Lesions more than 4 cm in size.</li></ul></li></ul></li><li><strong>Stage II: </strong>The carcinoma extends beyond the uterus, but has not extended onto the pelvic wall or to the lower third of vagina.<ul><li>Stage IIA: Involvement of up to the upper 2/3 of the vagina. No obvious parametrial involvement.<ul><li>Stage IIA1: Lesions not more than 4 cm in size.</li><li>Stage IIA2: Lesions more than 4 cm in size. </li></ul></li><li>Stage IIB: Obvious parametrial involvement but not onto the pelvic sidewall.</li></ul></li><li><strong>Stage III: </strong>The carcinoma has extended onto the pelvic sidewall. On rectal examination, there is no cancer free space between the tumour and pelvic sidewall. The tumour involves the lower third of the vagina. All cases of hydronephrosis or non-functioning kidney should be included unless they are known to be due to other causes.<ul><li>Stage IIIA: Involvement of the vagina but no extension onto the pelvic side wall.</li><li>Stage IIIB: Extension onto the pelvic sidewall, or hydronephrosis/non-functioning kidney.</li></ul></li><li><strong>Stage IV: </strong>The carcinoma has extended beyond the true pelvis, or has clinically involved the mucosa of the bladder and/or rectum.<ul><li>Stage IVA: Spread to adjacent pelvic organs.</li><li>Stage IVB: Spread to distant organs.</li></ul></li></ul><!-- end field 34efe91d-9f2e-42ee-9a1a-0db9d5fec6a7 --><!-- end item 67e4f27c-4a09-4114-8ae9-de208b4961e2 -->","subChapters":[{"id":"ac7e2d2d-f449-564f-9915-d141d919cadc","slug":"basis-for-recommendation-7b3","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 1945e27b-11a1-4875-9f8d-72e49ab86d4a --><h4>Basis for recommendation</h4><!-- end field 1945e27b-11a1-4875-9f8d-72e49ab86d4a -->","summary":null,"htmlStringContent":"<!-- begin item 7b3b4cf6-3ff3-4e1e-8f38-03bf3030a7fd --><!-- begin field 710a4242-418d-4732-a9f8-adb1a39d75cc --><p>This information is based on the British Medical Journal (BMJ) best practice guideline <em>Cervical cancer</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">BMJ, 2016</a>], and the Fédération Internationale des Gynaecologistes et Obstetristes (FIGO) guideline <em>FIGO staging for carcinoma of the vulva, cervix, and corpus uteri </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">FIGO, 2014</a>].</p><!-- end field 710a4242-418d-4732-a9f8-adb1a39d75cc --><!-- end item 7b3b4cf6-3ff3-4e1e-8f38-03bf3030a7fd -->","subChapters":[]}]},{"id":"ae7c8aac-59e5-536e-94f9-ed8769473c44","slug":"treatment","fullItemName":"Treatment","depth":3,"htmlHeader":"<!-- begin field 77fce994-5c96-4545-9e46-f282651aa1d1 --><h3>How is cervical cancer treated in secondary care? </h3><!-- end field 77fce994-5c96-4545-9e46-f282651aa1d1 -->","summary":null,"htmlStringContent":"<!-- begin item 91a75402-d5a5-4f3c-9fe2-c4c7b7cce450 --><!-- begin field 8eb2f187-8aca-41f7-9a1b-59f719617ddd --><p>Treatment decisions are based on the <a class=\"topic-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/management/management/#staging\">stage</a> of the disease. In the UK, computed tomography, magnetic resonance imaging, and positron emission tomography (PET) are also used to assess the extent of the disease. </p><ul><li><strong>In women with cervical intraepithelial neoplasia (CIN)</strong>:<ul><li>Colposcopy.<ul><li>Biopsy and histological analysis.</li><li>If moderate to severe abnormalities are found: excision or ablation.</li></ul></li></ul></li><li><strong>In women diagnosed with cervical cancer at FIGO</strong>:<ul><li>Stage IA1 (microinvasive disease): <ul><li>The disease may be managed conservatively. Lymphadenectomy is not required in the absence of lymphovascular invasion.</li></ul></li><li>Stages IA2-IIA (early stage disease):<ul><li>For tumours 4 cm or less, radical hysterectomy with lymphadenectomy is preferred to chemoradiation. </li><li>For tumours larger than 4 cm, chemoradiation is preferred. </li><li>If the woman wishes to preserve her fertility, then depending on the stage and whether lymphatic-vascular space invasion is present, radical trachelectomy and lymphadenectomy may be considered instead of radical hysterectomy for tumours smaller than 2 cm.</li></ul></li><li>Stage IIB-IVA (locally advanced disease): <ul><li>Chemoradiation is first-line therapy.</li></ul></li><li>Stage IVB (metastatic disease): <ul><li>Combination chemotherapy is the treatment of choice.</li><li>Alternatively, single agent therapy and palliative care may be suitable.</li></ul></li></ul></li><li><strong>In women who are pregnant:</strong><ul><li>Care from the multidisciplinary team and delivery after 35 weeks is the treatment of choice.</li></ul></li><li><strong>If the cervical cancer recurs, </strong>management should take into account previous treatment, location, the disease-free interval, symptoms, performance status, and the degree of benefit. Options include:<ul><li>Surgery (salvage): pelvic exenteration is possible if the relapse is confined to the central pelvis and chemotherapy and radiotherapy have failed.</li><li>Chemotherapy — palliative.</li><li>Supportive care only.</li></ul></li></ul><!-- end field 8eb2f187-8aca-41f7-9a1b-59f719617ddd --><!-- end item 91a75402-d5a5-4f3c-9fe2-c4c7b7cce450 -->","subChapters":[{"id":"69ac7d00-0814-5407-8c64-87479f7e90c6","slug":"basis-for-recommendation-231","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field e55068a6-56b8-410f-aa74-ff0b76a1c89c --><h4>Basis for recommendation</h4><!-- end field e55068a6-56b8-410f-aa74-ff0b76a1c89c -->","summary":null,"htmlStringContent":"<!-- begin item 2318d43f-fe6a-4074-a4d0-9e1f0f54d40e --><!-- begin field 4aa06373-55b3-4a88-b5fc-a1f4d937f030 --><p>This information is based on the British Medical Journal (BMJ) best practice guideline <em>Cervical cancer</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">BMJ, 2016</a>], the European Society for Medical Oncology (ESMO) <em>Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">ESMO, 2012</a>], the Public Health England (PHE) guideline <em>Colposcopy and programme management: guidelines for the NHS cervical screening programme </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">PHE, 2016</a>], and a narrative review <em>Management of recurrent cervical cancer: a review of the literature</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">Peiretti, 2012</a>].</p><h5>Conservative management of FIGO stage Ia1 </h5><ul><li>Microinvasive squamous cancer, International Federation of Gynaecology and Obstetrics (FIGO) stage IA1, can be managed by local excisional techniques if the excision margins are free of both CIN and invasive disease, and the histology has been reviewed by a pathologist [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">PHE, 2016</a>].</li></ul><!-- end field 4aa06373-55b3-4a88-b5fc-a1f4d937f030 --><!-- end item 2318d43f-fe6a-4074-a4d0-9e1f0f54d40e -->","subChapters":[]}]},{"id":"34b11869-d341-511f-b0e6-628b4aa12426","slug":"advanced-disease","fullItemName":"Advanced disease","depth":3,"htmlHeader":"<!-- begin field c13c4558-d7d6-4c26-9e52-760aaaff21d4 --><h3>How should I manage a women with advanced cervical cancer?</h3><!-- end field c13c4558-d7d6-4c26-9e52-760aaaff21d4 -->","summary":null,"htmlStringContent":"<!-- begin item 908112a3-c4b2-4782-9947-51f0c52d16b8 --><!-- begin field e641c34f-e520-4038-a8db-a89a9e2b6c3a --><p>Women with incurable cervical cancer should be managed on an individual basis with the primary healthcare professional as part of a multidisciplinary team. For general information on primary care management at the end of life, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/palliative-care-general-issues/\">Palliative care - general issues</a>.</p><p>Primary care clinicians should be aware of the distressing problems that are associated specifically with advanced cervical cancer for whom the following treatments may be appropriate.</p><ul><li><strong>Pain </strong>— early specialist referral for consideration of:<ul><li>Nerve-blocking procedures in addition to analgesics.</li><li>Spinal therapy (using opiates, local anaesthetics, and clonidine) to provide regional blockade for pelvic pain, pain from bony metastases, or neuropathic pain.</li><li>Percutaneous cementoplasty for bony metastases.</li></ul></li><li><strong>Renal failure </strong>due to ureteric obstruction — options include:<ul><li>No treatment.</li><li>Percutaneous nephrostomy.</li><li>Retrograde stenting.</li></ul></li><li><strong>Bleeding and thrombosis </strong>problems:<ul><li><strong>Deep vein thrombosis </strong>— low-molecular-weight heparin is more effective than oral anticoagulants.</li><li><strong>Minor vaginal bleeding </strong>— may respond to oral or topical tranexamic acid or radiotherapy.</li><li><strong>Massive haemorrhage </strong>may occur due to erosion of a major artery, and may lead to death. Relieve distress promptly and discuss management with the multidisciplinary team. Consider using midazolam for its anxiolytic effect, or diamorphine for its hypotensive effect, if admission is not deemed to be appropriate.</li></ul></li><li><strong>Malodour </strong>— management is dependent on the cause.<ul><li>If due to necrotic tissue. consider surgical debridement.</li><li>If it is due to fistula-related faecal incontinence, consider referral for defunctioning colostomy.</li><li>If it is due to fistula-related urinary incontinence, consider referral for bilateral percutaneous nephrostomy.</li></ul></li><li><strong>Lymphoedema </strong>of the legs.<ul><li>Refer to a specialist for consideration of conservative treatments, such as decongestant lymphatic therapy with compression bandaging, manual lymph drainage, and massage, and ensure good skin care and exercise.</li><li>Ensure prompt treatment of cellulitis.</li><li>Give advice about avoidance of injury.</li></ul></li></ul><!-- end field e641c34f-e520-4038-a8db-a89a9e2b6c3a --><!-- end item 908112a3-c4b2-4782-9947-51f0c52d16b8 -->","subChapters":[{"id":"a4b4dec7-b186-5d79-bb76-46b1bb7c87b2","slug":"basis-for-recommendation-dd2","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 3c82e55c-c5e0-41fe-9e9e-fea193786b86 --><h4>Basis for recommendation</h4><!-- end field 3c82e55c-c5e0-41fe-9e9e-fea193786b86 -->","summary":null,"htmlStringContent":"<!-- begin item dd23776e-d1ae-4404-908b-a82bd98ce7fd --><!-- begin field 772ee2c8-7263-4fbd-ba45-2a12d7a08bd9 --><p>These recommendations are based on the Scottish Intercollegiate Guidelines Network (SIGN) guideline <em>Management of cervical cancer</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">SIGN, 2008</a>].</p><!-- end field 772ee2c8-7263-4fbd-ba45-2a12d7a08bd9 --><!-- end item dd23776e-d1ae-4404-908b-a82bd98ce7fd -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}